The PBAC has reaffirmed its decision that Panadol Osteo should be delisted.
“The PBAC assessed the issues raised in the correspondence, but did not consider that there was any basis to revisit its earlier recommendations in this regard,” it has said in outlining the outcome of its consideration on the fate of the medicine.
The Pharmacy Guild requested late last year that the PBAC review its decision to delist certain medicines which are also available over the counter from general availability on the PBS, with particular emphasis on the paracetamol 665mg and Panadol Osteo.
However the PBAC did not recommend the restoration of PBS subsidised paracetamol 665 mg for persistent pain associated with osteoarthritis (or restoration of the other OTC medicines for which restrictions were modified in January 2016) beyond the current listings.
More on this tomorrow.